Regulators raised concerns with two of the company's drug candidates.
News & Analysis: Sarepta Therapeutics
Here's what bargain biotech shoppers need to know about Sarepta's future.
The biotech is reeling following the thumbs-down for its experimental DMD drug golodirsen.
These stocks led the broader market lower.
A surprise rejection is weighing on Sarepta's shares today.
Its high-profile DMD gene-therapy candidate hit an unexpected stumbling block.
Earnings and other bad news hit these stocks hard.
SRPT earnings call for the period ending June 30, 2019.
Great news for the biotech's lead drug. Not-so-great news for its bottom line.
These stocks led markets higher to close the first half of 2019.